Entera Bio (ENTX)
(Real Time Quote from BATS)
$2.02 USD
0.00 (0.00%)
Updated Aug 6, 2025 10:56 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ENTX 2.02 0.00(0.00%)
Will ENTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ENTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENTX
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates
Are Medical Stocks Lagging Argenx (ARGX) This Year?
ENTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Other News for ENTX
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 ...
Entera Bio (ENTX) Gains FDA Support for Phase 3 Osteoporosis Drug Study
Entera Bio receives FDA agreement on BMD as primary endpoint for EB613 study
Entera Bio (ENTX) Highlights Dual Action of EB613 at ASBMR 2025 | ENTX Stock News
Entera Bio announces data for EB613 to be presented at ASBMR 2025